Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.

Tan WS, Panchal A, Buckley L, Devall AJ, Loubière LS, Pope AM, Feneley MR, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths TRL, Page T, Hodgson D, Datta SN, Billingham LJ, Kelly JD.

Eur Urol. 2018 Sep 28. pii: S0302-2838(18)30655-9. doi: 10.1016/j.eururo.2018.09.005. [Epub ahead of print]

PMID:
30274699
2.

Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making.

Yap C, Billingham LJ, Cheung YK, Craddock C, O'Quigley J.

Clin Cancer Res. 2017 Dec 15;23(24):7440-7447. doi: 10.1158/1078-0432.CCR-17-0582. Epub 2017 Jul 21.

PMID:
28733440
3.

Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study.

Marsden JR, Fox R, Boota NM, Cook M, Wheatley K, Billingham LJ, Steven NM; NCRI Skin Cancer Clinical Studies Group, the U.K. Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group.

Br J Dermatol. 2017 May;176(5):1148-1154. doi: 10.1111/bjd.15112. Epub 2017 Apr 10.

PMID:
27714781
4.

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).

Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND.

BJU Int. 2017 Apr;119(4):522-529. doi: 10.1111/bju.13549. Epub 2016 Jul 10.

5.

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ.

JAMA Oncol. 2016 Apr;2(4):493-9. doi: 10.1001/jamaoncol.2015.5570.

6.

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.

Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ.

Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25.

7.

A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research.

Andronis L, Billingham LJ, Bryan S, James ND, Barton PM.

Med Decis Making. 2016 Apr;36(3):321-34. doi: 10.1177/0272989X15594369. Epub 2015 Jul 24.

PMID:
26209474
8.

Meta-analysis of randomized phase II trials to inform subsequent phase III decisions.

Burke DL, Billingham LJ, Girling AJ, Riley RD.

Trials. 2014 Sep 3;15:346. doi: 10.1186/1745-6215-15-346.

9.

Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis.

van Roekel EH, Cheng KK, James ND, Wallace DM, Billingham LJ, Murray PG, Bryan RT, Zeegers MP.

Int J Cancer. 2013 Jul 15;133(2):446-54. doi: 10.1002/ijc.28017. Epub 2013 Feb 13.

10.

Methodological considerations in the evaluation of radiotherapy technologies.

Burnet NG, Billingham LJ, Chan CS, Hall E, Macdougall J, Mackay RI, Maughan TS, Nutting CM, Staffurth JN, Illidge TM; National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group Executive Group.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):707-9. doi: 10.1016/j.clon.2012.06.003. Epub 2012 Jul 12. No abstract available.

PMID:
22795231
11.

Sample size calculations for designing clinical proteomic profiling studies using mass spectrometry.

Nyangoma SO, Collins SI, Altman DG, Johnson P, Billingham LJ.

Stat Appl Genet Mol Biol. 2012 Feb 10;11(3):Article 2. doi: 10.1515/1544-6115.1686.

PMID:
22499705
12.

Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.

Hubner RA, Riley RD, Billingham LJ, Popat S.

PLoS One. 2011;6(10):e25164. doi: 10.1371/journal.pone.0025164. Epub 2011 Oct 14.

13.

Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.

Bryan RT, Wei W, Shimwell NJ, Collins SI, Hussain SA, Billingham LJ, Murray PG, Deshmukh N, James ND, Wallace DM, Johnson PJ, Zeegers MP, Cheng KK, Martin A, Ward DG.

Proteomics Clin Appl. 2011 Oct;5(9-10):493-503. doi: 10.1002/prca.201100011. Epub 2011 Sep 6.

PMID:
21805675
14.

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.

Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T.

Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19. Review. No abstract available.

15.

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D.

J Clin Oncol. 2011 Apr 20;29(12):1531-8. doi: 10.1200/JCO.2010.30.3677. Epub 2011 Mar 21.

16.

Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma.

Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ, Graham N, Roberts C, Ryan G, Uppal H, Walker C, Young LS, Steven NM.

Gene Ther. 2011 Jun;18(6):584-93. doi: 10.1038/gt.2011.1. Epub 2011 Feb 10.

PMID:
21307889
17.

Radiotherapy research priorities for the UK.

Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS; NCRI Clinical and Translational Radiotherapy Research Working Group.

Clin Oncol (R Coll Radiol). 2010 Oct;22(8):707-9. doi: 10.1016/j.clon.2010.03.006. Epub 2010 Apr 2. No abstract available.

PMID:
20363111
18.

Modelling prognostic factors in advanced pancreatic cancer.

Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N.

Br J Cancer. 2008 Sep 16;99(6):883-93. doi: 10.1038/sj.bjc.6604568.

19.

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial.

Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K; WARP Collaborative Group, UK.

Lancet. 2009 Feb 14;373(9663):567-74. doi: 10.1016/S0140-6736(09)60205-1.

20.

Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison.

Cairns DA, Barrett JH, Billingham LJ, Stanley AJ, Xinarianos G, Field JK, Johnson PJ, Selby PJ, Banks RE.

Proteomics. 2009 Jan;9(1):74-86. doi: 10.1002/pmic.200800417.

PMID:
19053145
21.

Can we afford to ignore missing data in cost-effectiveness analyses?

Marshall A, Billingham LJ, Bryan S.

Eur J Health Econ. 2009 Feb;10(1):1-3. doi: 10.1007/s10198-008-0129-y. No abstract available.

PMID:
18936993
22.

Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom.

Gerrand CH, Billingham LJ, Woll PJ, Grimer RJ.

Sarcoma. 2007;2007:34128. doi: 10.1155/2007/34128.

23.

Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder.

Bryan RT, Billingham LJ, Wallace DM.

BJU Int. 2008 Mar;101(6):702-5; discussion 705-6. Epub 2007 Nov 13.

24.

Rational selection of patients for antibacterial prophylaxis after chemotherapy.

Cullen MH, Billingham LJ, Gaunt CH, Steven NM.

J Clin Oncol. 2007 Oct 20;25(30):4821-8.

PMID:
17947731
25.

Multiple testing issues in discriminating compound-related peaks and chromatograms from high frequency noise, spikes and solvent-based noise in LC-MS data sets.

Nyangoma SO, van Kampen AA, Reijmers TH, Govorukhina NI, van der Zee AG, Billingham LJ, Bischoff R, Jansen RC.

Stat Appl Genet Mol Biol. 2007;6:Article23. Epub 2007 Sep 8.

PMID:
17910529
26.

Estimating the cost-effectiveness of an intervention in a clinical trial when partial cost information is available: a Bayesian approach.

Lambert PC, Billingham LJ, Cooper NJ, Sutton AJ, Abrams KR.

Health Econ. 2008 Jan;17(1):67-81.

PMID:
17533622
27.

Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data.

Burton A, Billingham LJ, Bryan S.

Clin Trials. 2007;4(2):154-61.

PMID:
17456514
28.

Plasma proteome analysis reveals the geographical origin and liver tumor status of Dab (Limanda limanda) from UK marine waters.

Ward DG, Wei W, Cheng Y, Billingham LJ, Martin A, Johnson PI, Lyons BP, Feist SW, Stentiford GD.

Environ Sci Technol. 2006 Jun 15;40(12):4031-6.

PMID:
16830578
29.

Identification of serum biomarkers for colon cancer by proteomic analysis.

Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A.

Br J Cancer. 2006 Jun 19;94(12):1898-905. Epub 2006 Jun 6.

30.

Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis.

Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ.

Br J Cancer. 2006 Jan 30;94(2):287-92.

31.

Clinical trial design in hepatocellular carcinoma.

Johnson PJ, Billingham LJ.

Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):119-27. Review.

PMID:
15757808
32.

The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease.

Flavell KJ, Billingham LJ, Biddulph JP, Gray L, Flavell JR, Constandinou CM, Young LS, Murray PG.

Ann Oncol. 2003 Feb;14(2):282-90.

PMID:
12562657
33.

Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer.

Billingham LJ, Bathers S, Burton A, Bryan S, Cullen MH.

Lung Cancer. 2002 Aug;37(2):219-25.

PMID:
12140146
34.

Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease.

Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, Crocker J, Nelson P, Young LS, Murray PG.

Br J Haematol. 2002 Jul;118(1):195-201.

PMID:
12100148
35.

Simultaneous analysis of quality of life and survival data.

Billingham LJ, Abrams KR.

Stat Methods Med Res. 2002 Feb;11(1):25-48. Review.

PMID:
11923992
36.

The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer.

Billingham LJ, Cullen MH.

Ann Oncol. 2001 Dec;12(12):1671-5.

PMID:
11843243
37.

Palliative chemotherapy: no longer a contradiction in terms.

Archer VR, Billingham LJ, Cullen MH.

Oncologist. 1999;4(6):470-7. Review.

38.

Methods for the analysis of quality-of-life and survival data in health technology assessment.

Billingham LJ, Abrams KR, Jones DR.

Health Technol Assess. 1999;3(10):1-152. Review. No abstract available.

39.

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.

Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL.

J Clin Oncol. 1999 Oct;17(10):3188-94.

PMID:
10506617
40.

Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease.

Murray PG, Billingham LJ, Hassan HT, Flavell JR, Nelson PN, Scott K, Reynolds G, Constandinou CM, Kerr DJ, Devey EC, Crocker J, Young LS.

Blood. 1999 Jul 15;94(2):442-7.

41.

Quality assurance of CFU-GM assays: inter-laboratory variation despite standard reagents.

Lumley MA, Burton A, Billingham LJ, McDonald DF, Czarnecka HM, Milligan DW.

Eur J Haematol. 1999 Jan;62(1):32-7.

PMID:
9918309
42.

Expression of E-cadherin in oesophageal carcinomas from the UK and China: disparities in prognostic significance.

Jian WG, Darnton SJ, Jenner K, Billingham LJ, Matthews HR.

J Clin Pathol. 1997 Aug;50(8):640-4.

43.

Colony counting is a major source of variation in CFU-GM results between centres.

Lumley MA, Burgess R, Billingham LJ, McDonald DF, Milligan DW.

Br J Haematol. 1997 May;97(2):481-4.

PMID:
9163619
44.
45.

Quality assurance of CD34+ cell estimation in leucapheresis products.

Lumley MA, McDonald DF, Czarnecka HM, Billingham LJ, Milligan DW.

Bone Marrow Transplant. 1996 Oct;18(4):791-6.

PMID:
8899197
46.

High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.

Lumley MA, Milligan DW, Knechtli CJ, Long SG, Billingham LJ, McDonald DF.

Bone Marrow Transplant. 1996 Mar;17(3):383-8.

PMID:
8704691

Supplemental Content

Loading ...
Support Center